Rodrigo Sánchez-Bayona

MD, PhD. Oncólogo | Unidad de Cáncer de Mama y Ginecológico Hospital 12 de Octubre (Spain) | ESMO Young Oncologists Committee Chair

[Rodrigo Sánchez-Bayona @Rodrosb]

¡¡¡¡Soy Doctor en Medicina!!!! 👨🏼‍🎓

[Rodrigo Sánchez-Bayona @Rodrosb]

📣 Presented today at #ESMO26 with concomitant publication at @ESMO_Open
Results from the PROCURE Project, assessing genetic predisposition to ILD in patients treated with TDXd

[Rodrigo Sánchez-Bayona @Rodrosb]

🧬 New study from the PROCURE project in @ESMO_Open @myESMO explores the genetic basis of TDxD–induced ILD in breast cancer. 
📊 290 patients
• ILD incidence: 11.4%
• Strongest association mapped near HLA-F
• Additional signals SLCO1B1, CYP3A4

https://t.co/s9c5fqTcgL

[Rodrigo Sánchez-Bayona @Rodrosb]

@anelcabrera @PabloMando @matteolambe @E_de_Azambuja @PTarantinoMD

[Rodrigo Sánchez-Bayona @Rodrosb]

At 15y analyses, extended ET did not show an OS benefit. Now both adjuvant abema and ribo have positive OS results. Do you think there is still a role for extending ET after adjuvant CDK4/6i?
#ESMO26 #ESMOAmbassadors @myESMO

[Rodrigo Sánchez-Bayona @Rodrosb]

Now at #ESMO26 new phase 3 evidence for novel antiHER2 ADCs in HER2low MBC.
The question is: is chemotherapy still a valid comparator in this setting where TDXd has become a new standard?
#ESMOAmbassadors @myESMO

[Hongcheng Zhu 祝鸿程 @DrHongchengZhu]

#ESMO26 kicks off in Madrid 🇪🇸 today!
As an @myESMO YOC member, I'm excited to share our Young Oncologists Programme!
🎓 Mentorship
🩺 Clinical cases
🔬 Research & career development
📅 23–26 Oct
Join us and connect with the next generation of oncology! 🌍
#ESMOYOC

[ESMO - Eur. Oncology @myESMO]

Attending #ESMO26? 📱Download the ESMO Events App to browse the programme, save your must-attend sessions and create your personalised agenda before you arrive.
A simple step to help you make the most of your congress experience from day one.
🔗 https://t.co/v8caD1qlr8

[ESMO - Eur. Oncology @myESMO]

New at #ESMO26: the ESMO Principles for Humanising Scientific Reporting.
Designed to strengthen the communication of oncology research while maintaining scientific rigour and patient relevance.
🔗 https://t.co/5xt653oZdS

[SEOM @_SEOM]

📰 @ESMO_Open publica el paper 'Germline pharmacogenetic variants associated with trastuzumab deruxtecan-induced interstitial lung disease in advanced breast cancer: PROCURE project', un estudio multicéntrico presentado por el Dr. @Rodrosb en la Plenaria de #SEOM26

🔗 https://t.co/YAoo6nc4B4

[Rodrigo Sánchez-Bayona @Rodrosb]

🧬 New study from the PROCURE project in @ESMO_Open @myESMO explores the genetic basis of TDxD–induced ILD in breast cancer. 
📊 290 patients
• ILD incidence: 11.4%
• Strongest association mapped near HLA-F
• Additional signals SLCO1B1, CYP3A4

https://t.co/s9c5fqTcgL

[Elisabetta Bonzano MD, PhD @to_be_elizabeth]

📌 2nd International Multidisciplinary Consensus on the Integration of Radiation Therapy with New Systemic Treatments @ESTRO_RT
🧬PARPi and Immunotherapy in Breast
Cancer: Clinical Evidence, Patient Selection and Therapeutic Indications
@Rodrosb 🇪🇸
#FlorenceConsensus26 @OncoAlert #OncoAlertAF

[Luca Arecco, MD @Lucarecco]

Superb @Rodrosb brings the systemic therapy perspective.

PARP inhibitors and immunotherapy in #BreastCancer: which patients, which indications, and how strong is the evidence? Key discussion on combining these agents with RT!
@OncoAlert @KaidarOrit

[Icro Meattini @Icro_Meattini]

Orit Kaidar Person and Rodrigo Sanchez Bayona dance showing radiobiological rationale and clinical evidence for combination of PARPi and ICIs with #radiotherapy in #BreastCancer

#FlorenceConsensus26 #OncoAlert @OncoAlert @ESTRO_RT @myESMO

[SEOM @_SEOM]

🔴 Plenaria #SEOM26

📰 Identifican genes relacionados con el riesgo de neumonitis por trastuzumab-deruxtecán en pacientes con cáncer de mama

🩺 Dr. @Rodrosb, secretario científico de @_SEOM y oncólogo médico del @H12Octubre

https://t.co/MUPRjcREA1

[ESMO Open @ESMO_Open]

Outcomes of elacestrant in pts with ER+ HER2, ESR1m metastatic breast cancer who received prior ET & CDK4/6 inhibitor in a RW setting in @ESMO_Open.Durable benefit of elacestrant with 8.2 months of mTTNT after 1 to 2 lines of ET+CDK4/6i. https://t.co/p756cGNrxa

[OncoDailyBreast @OncoDailyBreast]

Managing HR+/HER2- Early Breast Cancer in the Genomic Era - Rodrigo Sanchez Bayona (@Rodrosb)

https://t.co/bBwXbnG8Bp

[OncoDaily @oncodaily]

@Rodrosb We would like to inform you that your post has been published on OncoDaily. Thank you for sharing.
https://t.co/r5yvvOdTHZ

[Rodrigo Sánchez-Bayona @Rodrosb]

And this work was made during a Clinical Unit Visit Fellowship of Dr Maria Illia (from Argentina) at our Institution @H12Octubre thanks to @myESMO

@PTarantinoMD @PabloMando @matteolambe @E_de_Azambuja @GuiNaderMarta @TeresaSAmaral

[Rodrigo Sánchez-Bayona @Rodrosb]

New paper on the management of HR+/HER2- early breast cancer in the genomic era! 🧬
Here are the real-world outcomes on how intermediate-risk (i-ROR) PAM50 patients fit into the new landscape of adjuvant CDK4/6 inhibitors:

https://t.co/BqsPQRjKge

[Rodrigo Sánchez-Bayona @Rodrosb]

In total, nearly half (48.6%) of these intermediate-risk patients met the criteria for at least one adjuvant iCDK4/6. This highlights the need to refine risk stratification and carefully consider adjuvant systemic therapies, like iCDK4/6, even when genomic scores are intermediate